Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2017

View Archived Issues

Novartis and Allergan collaborate on phase IIb study in NASH

OncoMed reports endpoint not met in tarextumab study, discontinuation of brontictuzumab trial

ADDF investment supports progression of NDX-1017 towards phase I trials for Alzheimer's disease

argenx achieves preclinical milestone with ARGX-115 under AbbVie collaboration

BioSpecifics opens phase I study of Xiaflex for uterine fibroids

AAV8-whirlin restores balance and auditory function in preclinical model of Usher syndrome

Ionis and Ribo collaborate on RNA-targeted therapeutics in China

Interim results from a phase II trial of tetravalent dengue vaccine candidate

Regen identifies new series of compounds that activate NR2F6 nuclear receptor

Encouraging 24-week data reported from phase III study of burosumab in X-linked hypophosphatemia

Cardinal Health to acquire select businesses from Medtronic's PMR division

First report of a novel somatic mutation in PRKAR1A gene in Sertolli cell tumor

Nivalis Therapeutics and Alpine Immune Sciences to merge

Temple University, Cognition Therapeutics discover sigma-2 receptor ligands for Alzheimer's disease

Mateon reports interim data from FOCUS study of CA4P in platinum-resistant ovarian cancer

Cinclus Pharma enrolling participants in first-in-human trial of X-842

AstraZeneca targets Mcl-1 with AZD-5991 for hematological cancers

Argos updates status of ADAPT phase III trial of rocapuldencel-T in metastatic renal cell carcinoma

Ludwig Institute for Cancer Research identifies FEN1, ERCC5 and EXO1 nucleases inhibitors

Pfizer presents beta-secretase 1 inhibitors

The University of Florida discovers antimicrobial agents

ADX-102 granted U.S. orphan status for congenital ichthyosis

INCB-039110 receives FDA orphan designation for graft-versus-host disease

Vivace Therapeutics patents YAP1/TEAD interaction inhibitors

ADAMTSL3 found as a candidate biomarker in ischemic stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...